Tag: GlaxoSmithKline

Substance Use Disorders – The epidemiological mess more than a decade in the making

~ Jason Schwartz ~ 2 Comments

Yesterday, I posted about the epidemiological crisis being reported regarding an explosion in substance use disorders resulting in increases in untreated SUDs and low rates of problem recognition. (There's been a parallel explosion in recovery prevalence.) All of this was predictable. In fact, we were writing about it here 13 years ago. Despite the foreseeability … Continue reading Substance Use Disorders – The epidemiological mess more than a decade in the making

Cash, sexual favors and drugs

~ Jason Schwartz ~ 4 Comments

Cash, sexual favors and drugs. We're not talking about a dope house. Some people (and companies) never learn: ...last week, UK pharma firm GlaxoSmithKline admitted that Chinese doctors were bribed by its execs with cash and sexual favours in return for prescribing the company's drugs. That coincided with rival AstraZeneca having its Shanghai office raided … Continue reading Cash, sexual favors and drugs

GlaxoSmithKline’s corruption

~ Jason Schwartz ~ 2 Comments

The details are simultaneously exactly what you'd expect and shocking. And some people wonder why we're reluctant to embrace the latest and greatest pharmacological fad. Keep all of this in mind next time someone suggests that medicalizing addiction treatment will improve professionalism, ethics and reliance on scientific evidence. Sham advisory boards: Glaxo also used sham … Continue reading GlaxoSmithKline’s corruption

Addiction diagnoses to rise

~ Jason Schwartz ~ 3 Comments

I've posted before about problems with the proposed approach to addiction in the DSM-5. These changes were intended to clear up language problems, specifically the conflation of dependence and addiction leading to "false positives" for addiction. Looks like the DSM-5 is causing its own language problems before it's even adopted. [emphasis mine] Many scholars believe … Continue reading Addiction diagnoses to rise